RxDoctor Payments Data

Mei Yi Worton

Acute Care · Tampa, FLNPI 1538805783

Payments from drug & device makers

$769in general payments, 2019–2025

Across 14 payments — averaging $54.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$176
  • Boston Scientific$149
  • Mallinckrodt Hospital Products Inc.$125
  • Ipsen Biopharmaceuticals, Inc$125
  • Novo Nordisk$120
  • Mirum Pharmaceuticals, Inc.$29
  • plus $45 from 2 others

What the payments were for

  • Food & beverage$769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$769 in reported general payments places this provider in the 65th percentile of 1,150 acute care providers in Florida.

See all acute care providers in Florida

Medicare billing

Part B allowed, 2024
$9,204
Medicare patients
84
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin222$689,560
EpclusaSofosbuvir/Velpatasvir24$573,793
OcalivaObeticholic Acid13$99,810
VemlidyTenofovir Alafenamide24$31,466
Envarsus XrTacrolimus31$27,159
Ursodiol54$5,901
Tacrolimus43$5,387
Lactulose106$3,777
Midodrine Hcl18$1,303
Mycophenolate Mofetil16$695
Spironolactone76$676
Bumetanide21$587
Carvedilol102$389
Amiloride Hcl22$308
Furosemide71$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Vemlidy$176$605,25948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,150 acute care providers in Florida.

Other acute care in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →